WO2013022257A3 - Composition de prévention et de traitement du cancer du poumon non à petites cellules contenant des dérivés de pyrazino-triazine - Google Patents

Composition de prévention et de traitement du cancer du poumon non à petites cellules contenant des dérivés de pyrazino-triazine Download PDF

Info

Publication number
WO2013022257A3
WO2013022257A3 PCT/KR2012/006260 KR2012006260W WO2013022257A3 WO 2013022257 A3 WO2013022257 A3 WO 2013022257A3 KR 2012006260 W KR2012006260 W KR 2012006260W WO 2013022257 A3 WO2013022257 A3 WO 2013022257A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
pyrazino
lung cancer
small cell
cell lung
Prior art date
Application number
PCT/KR2012/006260
Other languages
English (en)
Korean (ko)
Other versions
WO2013022257A2 (fr
Inventor
차주영
이관후
정지은
Original Assignee
제이더블유중외제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이더블유중외제약 주식회사 filed Critical 제이더블유중외제약 주식회사
Priority to KR1020147000757A priority Critical patent/KR101930859B1/ko
Priority to EP12821445.9A priority patent/EP2754441B1/fr
Priority to JP2014524925A priority patent/JP6059224B2/ja
Priority to ES12821445.9T priority patent/ES2577863T3/es
Priority to US14/237,641 priority patent/US9353119B2/en
Priority to CN201280039068.XA priority patent/CN103930113B/zh
Publication of WO2013022257A2 publication Critical patent/WO2013022257A2/fr
Publication of WO2013022257A3 publication Critical patent/WO2013022257A3/fr
Priority to HK15100319.7A priority patent/HK1199830A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne une composition qui contient des dérivés de pyrazino-triazine, des isomères de ceux-ci, ou des sels pharmaceutiquement acceptables de ceux-ci. La composition présente des effets supérieurs dans la prévention et le traitement du cancer du poumon non à petites cellules (NSCLC).
PCT/KR2012/006260 2011-08-09 2012-08-07 Composition de prévention et de traitement du cancer du poumon non à petites cellules contenant des dérivés de pyrazino-triazine WO2013022257A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020147000757A KR101930859B1 (ko) 2011-08-09 2012-08-07 피라지노-트리아진 유도체를 포함하는 비소세포성폐암 예방 및 치료용 조성물
EP12821445.9A EP2754441B1 (fr) 2011-08-09 2012-08-07 Composition de prévention et de traitement du cancer du poumon non à petites cellules contenant des dérivés de pyrazino-triazine
JP2014524925A JP6059224B2 (ja) 2011-08-09 2012-08-07 ピラジノ−トリアジン誘導体を含む非小細胞性肺癌の予防および治療用組成物
ES12821445.9T ES2577863T3 (es) 2011-08-09 2012-08-07 Composición para la prevención y el tratamiento del cáncer de pulmón de células no pequeñas, que contiene derivados de pirazino-triazina
US14/237,641 US9353119B2 (en) 2011-08-09 2012-08-07 Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
CN201280039068.XA CN103930113B (zh) 2011-08-09 2012-08-07 用于预防和治疗非小细胞肺癌的包含吡嗪并三嗪衍生物的组合物
HK15100319.7A HK1199830A1 (zh) 2011-08-09 2015-01-12 用於預防和治療非小細胞肺癌的包含吡嗪並三嗪衍生物的組合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110079314 2011-08-09
KR10-2011-0079314 2011-08-09
US201161555428P 2011-11-03 2011-11-03
US61/555,428 2011-11-03

Publications (2)

Publication Number Publication Date
WO2013022257A2 WO2013022257A2 (fr) 2013-02-14
WO2013022257A3 true WO2013022257A3 (fr) 2013-06-13

Family

ID=47669067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006260 WO2013022257A2 (fr) 2011-08-09 2012-08-07 Composition de prévention et de traitement du cancer du poumon non à petites cellules contenant des dérivés de pyrazino-triazine

Country Status (9)

Country Link
EP (1) EP2754441B1 (fr)
JP (1) JP6059224B2 (fr)
KR (1) KR101930859B1 (fr)
CN (1) CN103930113B (fr)
ES (1) ES2577863T3 (fr)
PL (1) PL2754441T3 (fr)
PT (1) PT2754441E (fr)
TW (1) TWI557128B (fr)
WO (1) WO2013022257A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829331A (zh) * 2013-09-11 2016-08-03 株式会社棱镜制药 生产吡嗪并[2，1-c][1，2，4]三嗪化合物的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013332735A1 (en) * 2012-10-19 2015-06-04 Prism Pharma Co., Ltd. Treatment of Scleroderma using an inhibitor of CBP/catenin
WO2014061826A1 (fr) * 2012-10-19 2014-04-24 Hiroyuki Kouji Traitement de maladies hyperprolifératives et précancéreuses de la peau faisant intervenir un inhibiteur de cbp/caténine
RU2016130065A (ru) * 2013-12-25 2018-01-30 Призм Фарма Ко., Лтд. КРИСТАЛЛЫ (2) ПИРАЗИНО[2,1-c] [1,2,4] ТРИАЗИНОВОГО СОЕДИНЕНИЯ
KR20160099101A (ko) * 2013-12-25 2016-08-19 가부시키가이샤 프리즘 파마 피라지노[２,１－ｃ][１,２,４]트리아진 화합물의 결정 (１)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056311A1 (fr) * 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines et dérivés utiles comme inhibiteurs de kinases
KR20100085102A (ko) * 2007-10-15 2010-07-28 주식회사 중외제약 리버스턴 유사체의 신규 화합물 및 그의 용도(1)
WO2010120112A2 (fr) * 2009-04-15 2010-10-21 Choongwae Pharma Corporation Nouveaux composés du type mimétique à spire inversée, procédé pour leur préparation et utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
CA2462922C (fr) * 2001-10-12 2010-05-25 Choongwae Pharma Corporation Imitations de retournement et composition et procedes afferents
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20090009431A1 (en) 2007-07-05 2009-01-08 Seongnam Ryu Plasma display panel and plasma display apparatus
US8455488B2 (en) * 2008-06-06 2013-06-04 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
TWI531573B (zh) 2010-10-14 2016-05-01 Ｊｗ製藥公司 新穎反轉模擬物之化合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100085102A (ko) * 2007-10-15 2010-07-28 주식회사 중외제약 리버스턴 유사체의 신규 화합물 및 그의 용도(1)
WO2010056311A1 (fr) * 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines et dérivés utiles comme inhibiteurs de kinases
WO2010120112A2 (fr) * 2009-04-15 2010-10-21 Choongwae Pharma Corporation Nouveaux composés du type mimétique à spire inversée, procédé pour leur préparation et utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2754441A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829331A (zh) * 2013-09-11 2016-08-03 株式会社棱镜制药 生产吡嗪并[2，1-c][1，2，4]三嗪化合物的方法

Also Published As

Publication number Publication date
PT2754441E (pt) 2016-06-24
EP2754441B1 (fr) 2016-04-27
JP2014521718A (ja) 2014-08-28
CN103930113B (zh) 2016-08-17
TWI557128B (zh) 2016-11-11
TW201321383A (zh) 2013-06-01
EP2754441A2 (fr) 2014-07-16
JP6059224B2 (ja) 2017-01-11
KR101930859B1 (ko) 2018-12-19
KR20140044362A (ko) 2014-04-14
ES2577863T3 (es) 2016-07-19
EP2754441A4 (fr) 2015-03-25
WO2013022257A2 (fr) 2013-02-14
CN103930113A (zh) 2014-07-16
PL2754441T3 (pl) 2016-11-30

Similar Documents

Publication Publication Date Title
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
WO2010111406A3 (fr) Composés et leurs utilisations thérapeutiques
WO2011056021A3 (fr) Utilisation de dérivés de benzohétérocycle pour prévenir ou traiter un cancer ou pour inhiber la métastase cancéreuse
WO2012159085A3 (fr) Compositions et méthodes de traitement et de prévention du cancer par ciblage et inhibition de cellules souches cancéreuses
WO2012158672A3 (fr) Composés utilisés dans le traitement de la mucosite
WO2013040227A3 (fr) Composés thérapeutiques
WO2010032011A8 (fr) Thérapie antifongique
CA2881554C (fr) Methodes d'inhibition de la fascine
WO2013188268A8 (fr) Composition pharmaceutique ophtalmique topique contenant du pazopanib
WO2013022257A3 (fr) Composition de prévention et de traitement du cancer du poumon non à petites cellules contenant des dérivés de pyrazino-triazine
WO2012162513A3 (fr) Indéno-isoquinoléines à substitution alcool, diol et hydrate de carbone utilisées en tant qu'inhibiteurs de la topoisomérase
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
WO2015112705A3 (fr) Combinaisons thérapeutiques pour le traitement du cancer
WO2012170742A3 (fr) Traitement et prévention du cancer avec des antagonistes du hmgb1
WO2013155465A8 (fr) Dérivés de xanthine substituée
WO2012119006A3 (fr) Dérivés de composés amino-hétéroaryles substitués par des pyrazoles
UA110131C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ
WO2010107791A3 (fr) Composés de pyrazinoisoquinoline
WO2013081420A3 (fr) Dérivé de phénoxypropanol et composition pharmaceutique le contenant
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
PT2793946T (pt) Composição tópica filmogénica e uso da mesma para tratar ou prevenir a onicofagia
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12821445

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20147000757

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014524925

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14237641

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012821445

Country of ref document: EP